Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Analysts maintain a “Buy” consensus on Lumexa Imaging, with two buy ratings, two strong-buy ratings and one sell rating among five analysts. The average 12-month price target is $16.00, with recent targets ranging from $13.00 to $18.00.
• LMRI shares recently traded at $10.25, below the analyst average target and well below their 52-week high of $19.45. The stock has a market capitalization of approximately $984.8 million.
• Lumexa reported quarterly EPS of $0.20, beating the $0.03 consensus estimate by $0.17, on revenue of $264.16 million. The company’s fiscal 2026 EPS guidance is $0.71–$0.77.

Shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Get Free Report) have earned an average recommendation of "Buy" from the five analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.00.

A number of research firms have issued reports on LMRI. Barclays raised their target price on Lumexa Imaging from $9.00 to $13.00 and gave the company an "overweight" rating in a report on Friday, August 28th. UBS Group reiterated a "strong-buy" rating on shares of Lumexa Imaging in a research note on Monday. KeyCorp assumed coverage on Lumexa Imaging in a report on Thursday. They set an "overweight" rating and a $18.00 price objective on the stock. Wall Street Zen cut shares of Lumexa Imaging from a "buy" rating to a "hold" rating in a research report on Saturday, September 12th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 target price on Lumexa Imaging in a report on Thursday, August 13th.

Lumexa Imaging Price Performance

Shares of LMRI traded up $0.04 during mid-day trading on Monday, hitting $10.25. The company's stock had a trading volume of 13,341 shares, compared to its average volume of 728,330. The stock has a market capitalization of $984.81 million and a price-to-earnings ratio of -20.86. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a 50-day moving average price of $11.37 and a 200 day moving average price of $10.39.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. On average, research analysts predict that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Lumexa Imaging

Several hedge funds have recently added to or reduced their stakes in LMRI. Strs Ohio acquired a new stake in Lumexa Imaging in the 1st quarter worth about $38,000. PNC Financial Services Group Inc. acquired a new stake in shares of Lumexa Imaging during the first quarter valued at about $63,000. State of Wyoming acquired a new stake in Lumexa Imaging in the first quarter valued at $91,000. AXQ Capital LP acquired a new stake in Lumexa Imaging during the 2nd quarter valued at approximately $128,000. Finally, Bank of America Corp DE acquired a new stake in Lumexa Imaging during the second quarter worth approximately $200,000.

Lumexa Imaging Company Profile

Lumexa Imaging, Inc NASDAQ: LMRI is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.

The company's imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.

Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.